Please assess the completion status of the following clinical trial:

Trial Title: Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting within 12 hours from the onset of symptoms with STEMI~* Informed, written consent~Exclusion Criteria:~* Age \< 18 years or Age \> 75 years~* Active bleeding; bleeding diathesis; coagulopathy~* Increased risk of bradycardiac events~* History of gastrointestinal or genitourinary bleeding \<2 months~* Major surgery in the last 6 weeks~* History of intracranial bleeding or structural abnormalities~* Suspected aortic dissection~* Any other condition that may put the patient at risk or influence study results or investigator's opinion (severe hemodynamic instability, known malignancies or other comorbid conditions with life expectancy \<1 year)~* Administration in the week before the index event of clopidogrel, ticlopidine, prasugrel, ticagrelor, thrombolytics, bivalirudin, low-molecular weight heparin or fondaparinux .~* Concomitant oral or IV therapy with strong CYP3A inhibitors or strong CYP3A inducers, CYP3A with narrow therapeutic windows~* Known relevant hematological deviations: Hb \<10 g/dl, Thrombi. \<100x10\^9/l~* Use of coumadin derivatives within the last 7 days~* Chronic therapy with ticagrelor, prasugrel, clopidogrel or ticlopidine~* Known severe liver disease, severe renal failure~* Known allergy to the study medications~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ticagrelor mashed pills (Type: EXPERIMENTAL): Ticagrelor loading dose (LD) 180 mg as mashed pills
- Ticagrelor integral pills (Type: ACTIVE_COMPARATOR): Ticagrelor loading dose (LD) 180 mg as integral pills

Based on this trial design, predict the completion outcome and termination type (if applicable).